potent – Communicable Diseases Research

Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants

Article

Published on 2022-11-012022-11-15
Journal: Cell Reports
[Category] SARS, 변종, 진단,

Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron

Article

Published on 2022-11-012022-11-15
Journal: The Journal of Infectious Diseases
[Category] SARS, 변종, 진단,

Novel Regioselective Approach to Cyclize Phage-Displayed Peptides in Combination with Epitope-Directed Selection to Identify a Potent Neutralizing Macrocyclic Peptide for SARS-CoV-2

Article

Published on 2022-10-212022-11-15
Journal: ACS chemical biology
[Category] COVID19(2023년), SARS, 치료기술, 치료제,

Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction

Article

Published on 2022-10-192022-11-15
Journal: International Journal of Molecular Sciences
[Category] COVID19(2023년), SARS, 신약개발, 치료제,

[키워드] ACE2 ACE2 receptor acute respiratory syndrome addition anticipated antiviral efficacy blocker blocking cell entry Clinical use Combination component coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated develop disrupting docking drugs effective Effectiveness Efficacy effort ELISA ENhance Future HEK293T cells in silico Infection inhibit inhibitor inhibitors Interaction isolate kuwanon C lack mechanism of action Morus Alba Morus alba L. potent Prevent Pseudotyped virus receptor Replication RNA SARS-CoV-2 SARS-CoV-2 spike several limitation severe acute respiratory syndrome coronavirus 2 significantly spike Spike protein spike protein. spike S1 RBD supported target tested the SARS-CoV-2 Therapies Vero cells
[DOI] 10.3390/ijms232012516 PMC 바로가기

Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease

Article

Published on 2022-10-132022-11-15
Journal: Journal of medicinal chemistry
[Category] COVID19(2023년), SARS, 치료제,

Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA

Article

Published on 2022-10-012022-11-15
Journal: RMD Open
[Category] COVID19(2023년), SARS, 진단, 치료제,

Potent Inactivation of Human Respiratory Viruses Including SARS-CoV-2 by a Photoactivated Self-Cleaning Regenerative Antiviral Coating

Article

Published on 2022-09-142022-11-15
Journal: ACS applied materials & interfaces
[Category] SARS, 치료제,

[키워드] activity antiviral activity calicivirus circulating coating Complication coronavirus COVID-19 COVID-19 pandemic curtail demonstrated Effect Evidence greatly reduce Health Human implication inactivated Including Novel viruses OC43 pandemic parainfluenza virus Personal protective equipment photoactivated regenerative virucide platform potent progression public health Radiation regenerative resource respiratory rhinovirus RNA SARS-CoV SARS-CoV 2 SARS-CoV-2 self-cleaning surfaces self-sanitizing coating shown Spread TCID Treatment upconversion nanomaterials vaccinia virus vesicular stomatitis virus virucide. virus virus virus transmission viruses Zika virus
[DOI] 10.1021/acsami.2c11653 PMC 바로가기

The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate

강력한 항바이러스 약물 후보로서 SARS-CoV-2 3C 유사 프로테아제에 대한 펩티도미메틱 억제제의 구조 기반 설계

Article

Published on 2022-08-052022-09-11
Journal: European journal of medicinal chemistry
[Category] COVID19(2023년), SARS, 치료제,

[키워드] 3C Like protease 3CL 3CL pro acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 anti-SARS-CoV-2 Anti-viral anti-viral drug applied complexes Compound coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 deficiency described develop drug candidates effective inhibit inhibitor inhibitors inhibitory activity Like Medicine pathogen Peptidomimetic inhibitors potent Prevent Pro protease Protease inhibitor protein-ligand respiratory SARS-CoV-2 SARS-CoV-2. screened Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus structure-based design targeting the SARS-CoV-2 Transcription treat viral replication X-ray
[DOI] 10.1016/j.ejmech.2022.114458 PMC 바로가기 [Article Type] Article

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody

Spike S2 도메인 특이적 인간 중화 단일클론 항체의 직접적인 호흡기 투여에 의해 매개되는 강력한 보편적인 베타-코로나바이러스 치료 활성

Article

Published on 2022-07-212022-09-11
Journal: PLoS Pathogens
[Category] COVID19(2023년), MERS, SARS, 변종, 진단,

[키워드] (Beta acute respiratory syndrome acute respiratory syndrome coronavirus-2 Administered administration antibody Beta beta-coronavirus check conserved convalescent coronavirus coronavirus vaccine Delta demonstrated determine dose Epsilon Gamma hACE2 hamster hamsters Human human monoclonal antibodies Human monoclonal antibody IgG Immune escape in vivo infected with SARS-CoV-2 Infection infection with SARS-CoV-2 intranasal K18 Lineage mAb mAbs MERS-CoV mice monoclonal antibody Mortality Mutation neutralize SARS-CoV neutralized Neutralizing omicron plasma potent pre-fusion Prevent Prophylactic Recognition recognize reduced respiratory respiratory viral S1 and S2 S2 domain SARS-CoV Urbani SARS-CoV-2 SARS-CoV-2 delta SARS-CoV-2 spike screened Severe acute respiratory syndrome severe acute respiratory syndrome coronavirus-2 significantly spike subject subjects tested therapeutic activity therapeutic potential Vaccine variants of concern Viral virus weight loss β-coronavirus
[DOI] 10.1371/journal.ppat.1010691 PMC 바로가기 [Article Type] Article

Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity

1년 동안 SARS-CoV-2-특이적 T 세포 사이토카인 생성 반응에 대한 종단 평가는 질병 중증도와 관련된 더 큰 면역과 함께 다중 사이토카인 증식 반응의 지속성을 보여줍니다

Article

Published on 2022-07-132022-09-11
Journal: Journal of Virology
[Category] COVID19(2023년), SARS, 치료법,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 all subjects assessment average CD4 CD8 Cell Cell-mediated immunity clone coronavirus Coronaviruses Critical cytokine cytokine response Cytokines declined demonstrated dominant ELISPOT ELISpot assay envelope enzyme-linked immunosorbent epitope Epitopes Ex vivo female Frequency gamma interferon granzyme B greater GzmB highlight IFN-γ IL-2 immune immune modeling. Immunity immunodominant immunodominant epitope immunodominant epitopes induce Infection interferon interleukin interleukin 2 kill longitudinal male median membrane nucleocapsid observation other coronaviruses peaked persistence post-symptom onset potent predicted produced producing proliferative PSO reduced regions response robust SARS-CoV-1 SARS-CoV-2 seasonal coronavirus seasonal coronaviruses severe acute respiratory syndrome Coronavirus severe disease structural protein structural proteins subject survivor T cell T cell immunity T cell memory T cell response T cell responses T cells target cells Vaccine viral infections Year
[DOI] 10.1128/jvi.00509-22 PMC 바로가기 [Article Type] Article